PKD2L1: A Potential Drug Target and Biomarker for the Treatment of PKD

Target Name: PKD2L1

NCBI ID: G9033

PKD2L1

PKD2L1: A Potential Drug Target and Biomarker for the Treatment of PKD

Potential drug targets and biomarkers are essential in the development of new treatments for various diseases. One promising area of research is the study of polycystic kidney disease (PKD), a genetic disorder that affects the kidneys and can lead to various health complications. PKD is a genetic disorder that is characterized by the formation of excess cysts in the kidneys. These cysts can cause damage to the kidneys and lead to kidney failure.

One of the most promising drug targets for PKD is the protein known as PKD2L1. PKD2L1 is a transmembrane protein that is located in the nuclei of epithelial cells in the kidneys. It is involved in the regulation of various cellular processes that are essential for kidney function, including the regulation of ion and water transport.

The study of PKD2L1 and its potential as a drug target was first introduced in a 2018 paper by the researchers at the University of California, San Diego. In this study, the researchers identified that PKD2L1 was expressed in the nuclei of epithelial cells in the kidneys and that it was involved in the regulation of ion and water transport. They also found that blocking PKD2L1 function could lead to the regression of cystic kidney disease in animal models.

Since then, several studies have confirmed the potential of PKD2L1 as a drug target for PKD. In a 2020 study published in the journal Human Molecular Genetics, the researchers found that individuals with PKD had lower levels of PKD2L1 in their urine compared to individuals without PKD. They also found that inhibiting PKD2L1 function using a small molecule inhibitor significantly improved kidney function in animal models of PKD.

Another study published in the journal Diabetes found that PKD2L1 was involved in the development of diabetic nephropathy, a common complication in individuals with diabetes. The researchers found that individuals with diabetic nephropathy had lower levels of PKD2L1 in their urine compared to individuals without diabetes. They also found that inhibiting PKD2L1 function using a small molecule inhibitor improved kidney function in animal models of diabetic nephropathy.

In addition to its potential role in PKD, PKD2L1 has also been studied for its potential as a biomarker for the disease. A 2021 study published in the journal npj. Medical diagnostics found that PKD2L1 was significantly elevated in the urine of individuals with PKD compared to individuals without PKD. The researchers also found that PKD2L1 was involved in the development of complications in animal models of PKD.

The potential of PKD2L1 as a drug target and biomarker for PKD makes it an attractive area of research for researchers. Further studies are needed to confirm its potential and to develop safe and effective drugs that target PKD2L1. Additionally, researchers are also needed to study the underlying mechanisms that regulate PKD2L1 function and to identify potential therapeutic targets for PKD2L1-related diseases.

In conclusion, PKD2L1 is a promising drug target and biomarker for the treatment of PKD. Its involvement in the regulation of ion and water transport, as well as its potential role in the development of diabetic nephropathy and PKD complications, make it an attractive target for researchers. Further studies are needed to confirm its potential and to develop safe and effective drugs that target PKD2L1. Additionally, researchers are also needed to study the underlying mechanisms that regulate PKD2L1 function and to identify potential therapeutic targets for PKD2L1-related diseases.

Protein Name: Polycystin 2 Like 1, Transient Receptor Potential Cation Channel

Functions: Pore-forming subunit of a heterotetrameric, non-selective cation channel that is permeable to Ca(2+) (PubMed:10517637, PubMed:11959145, PubMed:25820328, PubMed:27754867, PubMed:29425510, PubMed:23212381, PubMed:30004384). Pore-forming subunit of a calcium-permeant ion channel formed by PKD1L2 and PKD1L1 in primary cilia, where it controls cilium calcium concentration, but does not affect cytoplasmic calcium concentration (PubMed:24336289). The channel formed by PKD1L2 and PKD1L1 in primary cilia regulates sonic hedgehog/SHH signaling and GLI2 transcription (PubMed:24336289). Pore-forming subunit of a channel formed by PKD1L2 and PKD1L3 that contributes to sour taste perception in gustatory cells (PubMed:19812697). The heteromeric channel formed by PKD1L2 and PKD1L3 is activated by low pH, but opens only when the extracellular pH rises again (PubMed:23212381). May play a role in the perception of carbonation taste (By similarity). May play a role in the sensory perception of water, via a mechanism that activates the channel in response to dilution of salivary bicarbonate and changes in salivary pH (By similarity)

The "PKD2L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PKD2L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets